[Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Colorectal cancer].
In Japan, colorectal cancer is the third most common cause of death from cancer. The recurrence rate after curative surgical treatment for colorectal cancer has been estimated at 30-40%, most frequently occurring within 3 years. Therefore, more accurate staging of recurrent colorectal cancer is required for more appropriate management decisions. This article focuses on the clinical value of PET with [18F]fluorodeoxyglucose (FDG) in the diagnosis of recurrent and primary colorectal cancers. The technical issues in clinical practice and the cost-effectiveness of FDG-PET in staging recurrent colorectal cancer will be covered.